ArticleMetabolic brain disease2026
6-Gingerol ameliorates high-fat, high-sucrose diet-induced metabolic dysfunction and depressive-like behaviors by attenuating neuroinflammation and oxidative stress.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-calorie diets cause metabolic syndrome, obesity, and emotional disturbances, with neurological consequences. These prevalent conditions impair both peripheral and central nervous system function, elevating depression risk. These complications represent prevalent chronic conditions in modern society. The bioactive compound 6-gingerol demonstrates antioxidant and anti-inflammatory properties. This study investigated 6-gingerol’s protective effects against depression-like behavior and metabolic syndrome induced by a high-fat, high-sucrose diet (HFHS) in rats. Male Sprague-Dawley rats were randomly divided into six groups (n = 8/group): normal control (balanced diet; 4.12 kcal/g), HFHS-fed (5.57 kcal/g + 0.8 kcal/mL), low-dose (100 mg/kg/day, oral 6-gingerol), high-dose (200 mg/kg/day, oral 6-gingerol), and HFHS-fed groups receiving low-dose (100 mg/kg/day) or high-dose (200 mg/kg/day) oral 6-gingerol for ten weeks. Behavioral tests (forced swim, tail suspension) were conducted. Measured parameters included fasting blood glucose, serum lipids, insulin, leptin, hs-CRP, neurochemical markers (BDNF, GABA, AChE), neurotransmitters (serotonin, dopamine), oxidative stress markers, and inflammatory cytokines. Brain tissues were analyzed histopathologically and immunohistochemically. Both 6-gingerol doses significantly (p < 0.05) improved hyperglycemia, insulin resistance, dyslipidemia, hs-CRP, and leptin levels. Glutathione and glutathione peroxidase increased, while malondialdehyde, protein carbonyl, nitric oxide, TNF-α, and IL-6 significantly decreased. Immobility time in forced swim and tail suspension tests was significantly reduced. Neurochemical and neurotransmitter markers in brain tissue improved significantly (p < 0.05). GFAP and iNOS expression was reduced (p < 0.05), showing dose dependency. Histopathological and histochemical analyses confirmed 6-gingerol’s neuroprotection. 6-Gingerol, especially at high dose, effectively alleviated HFHS-induced metabolic syndrome, and depression-like behavior. These findings underscore its potential as a prophylactic against neurobehavioral deficits, and diet-associated depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.